Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06311721
Status:
RECRUITING
Last Update Posted:
2024-07-12
First Post:
2024-03-08
Brief Title:
A Study to Compare ABP 234 and Keytruda Pembrolizumab in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Randomized Double-Blind Study to Compare Efficacy Pharmacokinetics Safety and Immunogenicity Between ABP 234 and Keytruda Pembrolizumab in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product Keytruda
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-508336-57 | EUDRACT_NUMBER | None | None |